fbpx

Day

October 10, 2017
Clinical Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Additional Nonclinical Data Show APX001 is Effective Against a Broad Range of Pathogenic Fungi, Including Deadly Candida auris SAN DIEGO – October 9, 2017 – Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001,...

News

Danish researchers provide proof: Caesarean sections can lead to asthma and allergies
12. November 2020
Brand-new medical treatment for cocaine addiction
10. November 2020
90 million to 18 Talented Researchers
19. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge